Gathering results from the clinical studies conducted with our Care Plans has allowed us to prove the effectiveness of the Medtep platform. We currently have the following ongoing clinical studies: Medtep Hemophilia, Medtep Asthma, Medtep DBT and Medtep Obesity.
These outcomes show increased treatment adherence and cost reduction, which encourages us at Medtep to keep on working towards a validated, affordable and cost-effective care.
Some of the main results from the Medtep Hemophilia study show patients reach an overall 89% treatment adherence and improve treatment compliance by 47% over usual treatment after 1 year using the platform.
From our Medtep Asthma study outcomes we should highlight that one-third of patients improved their level of control compared to that of base treatment in the first 6 months after using the platform contributing up to 25% annual cost reduction per patient to the National Health Service.
Moreover, an outstanding fact from the Medtep Obesity study was to observe that the average weight loss using Medtep platform was 2.5 times higher than the usual treatment and also that it was almost 6 times more effective to maintain at least 5% weight loss after a 12 months follow-up.
Also worth mentioning, Medtep DBT was presented at the 4th International Congress of Borderline Personality Disorder and Allied Disorders, in Vienna last September and results from the study are coming out soon.
Chief Medical Officer
Learn more about Medtep’s clinical studies at our outcomes page that is constantly updated with the latest information.